Physician profile
Donald Ho
NPI 1316913973
$592.92
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $14.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $117.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.26 | 2019 | |
| Mylan Specialty L.P. | $56.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $41.27 | 2019 | |
| Merck Sharp & Dohme LLC | $32.17 | 2019 | |
| Grifols USA, LLC | $24.55 | 2019 | |
| Insmed, INC. | $23.44 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.08 | 2019 | |
| Genzyme Corporation | $20.50 | 2019 | |
| Electromed, INC. | $20.01 | 2019 | |
| Pulmonx Corporation | $18.34 | 2019 | |
| Chiesi USA, INC. | $16.77 | 2019 | |
| Gilead Sciences, INC. | $16.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.01 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $12.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.